ASX Announcements
- 17 Sep 2024Initial Director's Interest Notice x2
- 17 Sep 2024New Appointments to the Board of Directors
- 17 Sep 2024Date of AGM & Closing Date For Director Nominations
- 06 Sep 2024Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
- 28 Aug 2024Appendix 4G & Corporate Governance Statement
- 28 Aug 2024Appendix 4E & Annual Report to 30 June 2024
- 14 Aug 2024Change of Director's Interest Notice
- 14 Aug 2024Notification regarding unquoted securities - AGN
- 14 Aug 2024Results of Meeting
- 08 Aug 2024Change of Director's Interest Notice x3
- 08 Aug 2024Cleansing Notice
- 08 Aug 2024Notification of cessation of securities - AGN
- 08 Aug 2024Application for quotation of securities - AGN
- 31 Jul 2024Quarterly Activities/Appendix 4C Cash Flow Report
- 24 Jul 2024Phase 2 Stroke Clinical Trial Update
- 22 Jul 2024Investor Webinar Presentation
- 15 Jul 2024Investor Presentation
- 12 Jul 2024Notice of General Meeting/Proxy Form
- 09 Jul 2024Notice of initial substantial holder from IFL
- 14 Jun 2024Cleansing Notice
- 14 Jun 2024Notification of cessation of securities - AGN
- 14 Jun 2024Application for quotation of securities - AGN
- 12 Jun 2024Notification of cessation of securities - AGN
- 05 Jun 2024Final Director's Interest Notice
- 05 Jun 2024Non-Executive Director Resignation
- 05 Jun 2024Change of Director's Interest Notice
- 05 Jun 2024Cleansing Notice
- 05 Jun 2024Notification of cessation of securities - AGN
- 05 Jun 2024Application for quotation of securities - AGN
- 15 May 2024ARG-007 Reduces Effects of TBI in Preclinical Study
- 29 Apr 2024DSMB Confirms Safety of First Patients Dosed
- 24 Apr 2024Quarterly Activities/Appendix 4C Cash Flow Report
- 22 Apr 2024Cleansing Notice
- 22 Apr 2024Application for quotation of securities - AGN
- 12 Apr 2024Proposed issue of securities - AGN
- 12 Apr 2024Proposed issue of securities - AGN
- 12 Apr 2024Argenica Successfully Completes $12.0m Placement
- 10 Apr 2024Trading Halt
- 10 Apr 2024Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
- 28 Mar 2024First Patient Dosed in Phase 2 Stroke Trial of ARG-007
- 25 Mar 2024FDA Grants Rare Pediatric Disease Designation For HIE
- 07 Mar 2024Application for quotation of securities - AGN
- 28 Feb 2024Half Yearly Report and Accounts
- 16 Feb 2024Application for quotation of securities - AGN
- 12 Feb 2024Phase 2 Manufacturing Completed & Trial Update
- 02 Feb 2024Cleansing Notice
- 02 Feb 2024Application for quotation of securities - AGN
- 31 Jan 2024Quarterly Activities/Appendix 4C Cash Flow Report
- 14 Dec 2023Phase 2 Stroke Clinical Trial Update
- 01 Dec 2023AGM Presentation
- 01 Dec 2023Initial Director's Interest Notice
- 01 Dec 2023Final Director's Interest Notice
- 01 Dec 2023Amended Constitution
- 01 Dec 2023Results of Annual General Meeting
- 30 Nov 2023Appointment of Non-Executive Chair
- 22 Nov 2023Argenica Appoints VP of Business Development
- 15 Nov 2023FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
- 13 Nov 2023Argenica Receives $2.09m R&D Tax Incentive Cash Rebate
- 03 Nov 2023ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
- 27 Oct 2023Board Update
- 27 Oct 2023Notice of Annual General Meeting/Proxy Form
- 26 Oct 2023Quarterly Activities/Appendix 4C Cash Flow Report
- 25 Oct 2023Investor Presentation
- 18 Oct 2023Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
- 29 Sep 2023Date of AGM & Closing Date For Director Nominations
- 12 Sep 2023Ethics Approval Received for Phase 2 Trial
- 12 Sep 2023Grant Awarded To Develop Additional Administration Route
- 04 Sep 2023Presentation - Fetal and Neonatal Scientific Conference
- 24 Aug 2023Presentation - Stroke 2023 Scientific Conference
- 23 Aug 2023Positive FDA Feedback Following Pre-Ind Meeting
- 23 Aug 2023Appendix 4G & Corporate Governance Statement
- 23 Aug 2023Appendix 4E & Annual Report 30 June 2023
- 18 Aug 2023Response to ASX Aware Query
- 03 Aug 2023Cleansing Notice
- 03 Aug 2023Application for quotation of securities - AGN
- 01 Aug 2023ARG-007 Prevents Uptake & Aggregation of Key Protein
- 25 Jul 2023Investor Presentation
- 24 Jul 2023Quarterly Activities/Appendix 4C Cash Flow Report
- 19 Jul 2023ARG-007 Phase 2 Clinical Trial Update
- 17 Jul 2023Ceasing to be a substantial holder
- 22 Jun 2023ARG-007 Protects Brain Cells in Moderate TBI Model
- 20 Jun 2023Becoming a substantial holder
- 13 Jun 2023Becoming a substantial holder
- 13 Jun 2023Application for quotation of securities - AGN
- 09 Jun 2023Notification regarding unquoted securities - AGN
- 09 Jun 2023Cleansing Notice
- 09 Jun 2023Application for quotation of securities - AGN
- 05 Jun 2023Release of Restricted Securities From Escrow
- 02 Jun 2023Proposed issue of securities - AGN
- 02 Jun 2023Argenica Successfully Completes $4.0m Placement
- 31 May 2023Trading Halt
- 15 May 2023Final Phase1 Clinical Trial Report
- 27 Apr 2023Quarterly Activities/Appendix 4C Cash Flow Report
- 20 Apr 2023Latest Preclinical HIE Study Results
- 30 Mar 2023Significant Non-Dilutive Funding For Preclinical HIE Studies
- 06 Mar 2023Interim Phase 1 Safety Report Confirms Safety of ARG-007
- 28 Feb 2023Half Yearly Report and Accounts
- 22 Feb 2023Non-Dilutive Funding Received to Progress Alzheimers Studies
- 09 Feb 2023Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
- 02 Feb 2023Investor Presentation
- 31 Jan 2023Quarterly Activities/Appendix 4C Cash Flow Report
- 20 Jan 2023Argenica Awarded $1.2m CRC-P Grant for TBI Project
- 21 Dec 2022Successful Completion of Phase 1 Clinical Trial Dosing
- 12 Dec 2022Ceasing to be a substantial holder
- 08 Dec 2022SRC Approves Commencement Of Fourth And Final Cohort Dosing
- 30 Nov 2022Change of Director's Interest Notice
- 30 Nov 2022Notification regarding unquoted securities - AGN
- 25 Nov 2022Phase 1 Clinical Trial Progress Update
- 25 Nov 2022AGM Presentation
- 25 Nov 2022Results of Annual General Meeting
- 18 Nov 2022Safety Review Committee Approves Third Cohort Commencement
- 07 Nov 2022Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
- 02 Nov 2022Safety Review Committee Approves Second Cohort
- 31 Oct 2022Quarterly Activities/Appendix 4C Cash Flow Report
- 26 Oct 2022No Serious Safety Issues Observed in First Cohort
- 21 Oct 2022Notice of Annual General Meeting/Proxy Form
- 20 Oct 2022Investor Presentation
- 17 Oct 2022First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
- 04 Oct 2022Argenica Receives $1.38m R&D Tax Incentive Cash Refund
- 29 Sep 2022Further Positive Preclinical Results for ARG-007 In HIE
- 16 Sep 2022Date of AGM and Closing Date for Director Nominations
- 08 Sep 2022Phase 1 Clinical Trial Summary
- 07 Sep 2022Argenica Receives Ethics Approval To Commence Phase 1 Trial
- 23 Aug 2022Appendix 4G & Corporate Governance Statement
- 23 Aug 2022Appendix 4E & Annual Report 30 June 2022
- 11 Aug 2022Ethics Application Submitted for Phase 1 Trial
- 29 Jul 2022Quarterly Activities/Appendix 4C Cash Flow Report
- 11 Jul 2022Clinical Advisory Committee Appointment
- 11 Jul 2022Notification regarding unquoted securities - AGN
- 07 Jul 2022Peer Reviewed Paper Published on Preclinical Safety Study
- 17 Jun 2022Investor Presentation - Updated
- 16 Jun 2022Change of Director's Interest Notice x2
- 14 Jun 2022Investor Presentation
- 10 Jun 2022Notification regarding unquoted securities - AGN
- 10 Jun 2022Cleansing Notice
- 10 Jun 2022Application for quotation of securities - AGN
- 03 Jun 2022Proposed issue of securities - AGN
- 03 Jun 2022Proposed issue of securities - AGN
- 03 Jun 2022Argenica Successfully Completes $5.5m Placement
- 01 Jun 2022Trading Halt
- 19 May 2022Successful Completion of Final Pre-Clinical PK Study
- 05 May 2022GLP Safety Studies Successfully Completed
- 29 Apr 2022Quarterly Activities/Appendix 4C Cash Flow Report
- 26 Apr 2022Maximum Tolerated Dose Successfully Established in Studies
- 04 Apr 2022Initial Director's Interest Notice
- 04 Apr 2022Argenica Appoints CEO Dr Liz Dallimore Managing Director
- 30 Mar 2022Positive Preclincal Data on Efficacy in New Indication
- 21 Mar 2022Peer Reviewed Paper Published on Preclinical Study
- 16 Mar 2022Investor Presentation
- 28 Feb 2022Change of Director's Interest Notice
- 24 Feb 2022Successful Completion of Final GLP Genotoxicity Studies
- 22 Feb 2022Half Yearly Report and Accounts
- 27 Jan 2022Quarterly Activities/Appendix 4C Cash Flow Report
- 24 Jan 2022Preliminary Pre-Clinical Tox Studies Successfully Completed
- 13 Jan 2022Argenica Appoints Head of Clinical Development
- 13 Jan 2022Notification regarding unquoted securities - AGN
- 31 Dec 2021Application for quotation of securities - AGN
- 17 Dec 2021Application for quotation of securities - AGN
- 10 Dec 2021Release of Restricted Securities from Escrow
- 09 Dec 2021Argenica to be Granted Patent Protection in the US
- 17 Nov 2021Results of Annual General Meeting
- 17 Nov 2021AGM Presentation
- 03 Nov 2021Positive Preclinical Data for ARG-007 Neuroprotection in HIE
- 28 Oct 2021Quarterly Activities/Appendix 4C Cash Flow Report
- 27 Oct 2021Investor Presentation
- 18 Oct 2021Phase 1 Clinical Trial Overview & Roadmap
- 15 Oct 2021Notice of Annual General Meeting/Proxy Form
- 14 Oct 2021Application for quotation of securities - AGN
- 04 Oct 2021Release of Restricted Securities from Escrow
- 30 Sep 2021Argenica Partners With Linear For Phase 1 Clinical Trial
- 21 Sep 2021Date of AGM & Closing Date for Director Nominations
- 14 Sep 2021Argenica Achieves Manufacturing Milestones
- 27 Aug 2021Appendix 4G & Corporate Governance Statement
- 27 Aug 2021Appendix 4E & Annual Report 30 June 2021
- 11 Aug 2021Appendix 3G
- 05 Aug 2021Proposed issue of securities - AGN
- 05 Aug 2021Issue of Options
- 29 Jul 2021Quarterly Activities/Appendix 4C Cash Flow Report
- 21 Jul 2021Grant Secured to Advance Pre-Clinical Studies Of ARG-007
- 13 Jul 2021Study Additional Information
- 12 Jul 2021Study Shows ARG-007 Does Not Degrade
- 01 Jul 2021Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study
- 30 Jun 2021Change of Registered Office
- 16 Jun 2021Investor Presentation
- 11 Jun 2021Argenica Commences Trading on ASX
- 09 Jun 2021Becoming a substantial holder
- 09 Jun 2021Becoming a substantial holder
- 09 Jun 2021Initial Director's Interest Notice x4
- 09 Jun 2021Confirmation Statements
- 09 Jun 2021Top 20 Holders
- 09 Jun 2021Distribution Schedule
- 09 Jun 2021Securities Trading Policy
- 09 Jun 2021Corporate Governance Statement
- 09 Jun 2021Employee Securities Incentive Plan
- 09 Jun 2021Interim Report for the period ended 31 December 2020
- 09 Jun 2021Annual Report for period from incorporation to 30 June 2020
- 09 Jun 2021Constitution
- 09 Jun 2021Prospectus
- 09 Jun 2021Appendix 1A & Information Form and Checklist
- 09 Jun 2021ASX Notice - Admission to Official List
